FMP
Interpace Biosciences, Inc.
IDXG
PNK
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
0.89 USD
-0.03 (-3.37%)
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
132.51M
170.36M
310.02M
363.14M
414.29M
561.12M
760M
1.03B
1.39B
1.89B
-
28.57
81.98
17.13
14.09
35.44
35.44
35.44
35.44
-39.8M
-38.71M
-130.92M
-110.34M
-71.19M
-159.98M
-216.68M
-293.48M
-397.5M
-538.38M
-30.03
-22.72
-42.23
-30.39
-17.18
-28.51
-28.51
-28.51
-28.51
-48.31M
-46.92M
-173.53M
-157.72M
-116.36M
-214.91M
-291.07M
-394.23M
-533.96M
-723.2M
-36.46
-27.54
-55.97
-43.43
-28.09
-38.3
-38.3
-38.3
-38.3
8.52M
8.21M
42.61M
47.38M
45.16M
54.92M
74.39M
100.75M
136.46M
184.82M
6.43
4.82
13.74
13.05
10.9
9.79
9.79
9.79
9.79
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)